发明名称 Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
摘要 Disclosed herein are methods of treating cancer in a subject, and methods for inhibiting growth, migration and/or invasion of a cancer cell in the subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof that downmodulates Fzd2. The antibody may specifically bind Fzd2, and may promote internalization of the Fzd2 receptor by the cancer cells and/or prevent ligand binding to Fzd2. Specific antibodies, and also specific portions of the Fzd2 molecule for antibody binding are disclosed. In one embodiment the antibody specifically binds to the epitope HGAEQICVGQNHSEDGAPAL (SEQ ID NO: 1). Specific cancers (e.g. late stage hepatocellular carcinoma), intended for treatment are provided, and include cancers that exhibit overexpression of Fzd2, and/or Wnt5a.
申请公布号 US9260519(B2) 申请公布日期 2016.02.16
申请号 US201214127017 申请日期 2012.06.15
申请人 PRESIDENT AND FELLOWS OF HARVARD COLLEGE 发明人 Gujral Taranjit S.;MacBeath Gavin
分类号 A61K39/395;C07K16/28;C07K16/30;A61K39/00 主分类号 A61K39/395
代理机构 Nixon Peabody LLP 代理人 Nixon Peabody LLP ;Resnick David S.;Huff Shayne Y.
主权项 1. A method of treating cancer in a subject that exhibits overexpression of Fzd2 or overexpression of Wnt5a comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds Fzd2 within a region corresponding to amino acids 125-163 and downmodulates Fzd2, such that the antibody or antigen binding fragment thereof is delivered to cancer cells of the subject, to thereby treat the cancer.
地址 Cambridge MA US